Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21st century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.